Antibody conjugates and therapeutic strategies

Paul McCarron, S. A. Olwill, W. M. Y. Marouf, R. J. Buick, B. Walker, C. J. Scott

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)


Immunotherapeutics represent the largest group of molecules currently in development as new drug entities. These versatile molecules are being investigated for the treatment of a range of pathological conditions including cancer, infectious and inflammatory diseases. Antibodies can be used to exert biological effects themselves or as delivery agents of conjugated drug molecules. Site-specific delivery of therapeutic agents has been an ultimate goal of the pharmaceutical industry in order to maximize drug action and minimize side effects. Antibodies have the potential to realize this objective and in this review we will examine some of the main strategies currently being employed for the development of these diverse therapeutic molecules.
Original languageEnglish
Pages (from-to)368-380
JournalMolecular Interventions
Issue number6
Publication statusPublished (in print/issue) - 2005

Bibliographical note

PT: J; TC: 9


Dive into the research topics of 'Antibody conjugates and therapeutic strategies'. Together they form a unique fingerprint.

Cite this